[go: up one dir, main page]

AR024313A1 - Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene - Google Patents

Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene

Info

Publication number
AR024313A1
AR024313A1 ARP000102831A ARP000102831A AR024313A1 AR 024313 A1 AR024313 A1 AR 024313A1 AR P000102831 A ARP000102831 A AR P000102831A AR P000102831 A ARP000102831 A AR P000102831A AR 024313 A1 AR024313 A1 AR 024313A1
Authority
AR
Argentina
Prior art keywords
microgranules
preparation
morphine sulfate
procedure
composition containing
Prior art date
Application number
ARP000102831A
Other languages
English (en)
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9546553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR024313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of AR024313A1 publication Critical patent/AR024313A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a una nueva formulacion oral de liberacion prolongada de sulfato de morfina en forma de microgránulos. Cada microgránulo comprendeun grano de soporte, neutro, rodeado por una capa activa y por una capa de liberacionprolongada, caracterizados porque la capa de liberacion prolongadacontiene un copolímero de ácido metacrílico y de éster de metil metacrilato, siendo la proporcion relativa entre los grupos carboxilos libres y los gruposésteres, igual aaproximadamente 0,5 y un a sílice que presenta un carácter hidrofobo. Se refiere también a un procedimiento para la preparacion de estosmicrogránulos enteramente llevado a cabo en un medio acuoso por montajes sobre los granos de soportes neutros.
ARP000102831A 1999-06-09 2000-06-07 Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene AR024313A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9907259A FR2794646B1 (fr) 1999-06-09 1999-06-09 Microgranules de sulfate de morphine, procede de preparation et composition les contenant

Publications (1)

Publication Number Publication Date
AR024313A1 true AR024313A1 (es) 2002-09-25

Family

ID=9546553

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000102831A AR024313A1 (es) 1999-06-09 2000-06-07 Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene
ARP080103672A AR068015A2 (es) 1999-06-09 2008-08-22 Microgranulos de sulfato de morfina procedimiento para su preparacion y composicion que los contiene

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080103672A AR068015A2 (es) 1999-06-09 2008-08-22 Microgranulos de sulfato de morfina procedimiento para su preparacion y composicion que los contiene

Country Status (24)

Country Link
US (2) US7063864B1 (es)
EP (3) EP1189602B1 (es)
JP (1) JP4296562B2 (es)
KR (1) KR100676123B1 (es)
CN (1) CN1267089C (es)
AR (2) AR024313A1 (es)
AT (2) ATE544448T1 (es)
AU (1) AU769160C (es)
BR (1) BRPI0011404B8 (es)
CA (1) CA2376339C (es)
CO (1) CO5160317A1 (es)
CY (1) CY1107612T1 (es)
DE (1) DE60033519T2 (es)
DK (2) DK1189602T3 (es)
ES (2) ES2280226T3 (es)
FR (1) FR2794646B1 (es)
HK (1) HK1045107B (es)
MX (1) MXPA01012751A (es)
NZ (1) NZ516077A (es)
PT (2) PT1627631E (es)
SI (1) SI1189602T1 (es)
TW (1) TWI224510B (es)
WO (1) WO2000074659A1 (es)
ZA (1) ZA200110087B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) * 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US20190038769A1 (en) * 2010-12-01 2019-02-07 Gowey Research Group, Pllc Micro-rna profiling, compositions, and methods of treating diseases
JP2012250926A (ja) * 2011-06-01 2012-12-20 Nitto Denko Corp 粒子製剤
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
CA3085348A1 (en) 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
GB9119958D0 (en) 1991-09-18 1991-10-30 Unilever Plc Detergent compositions
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
EP2036558A3 (en) * 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant

Also Published As

Publication number Publication date
BR0011404A (pt) 2002-03-05
EP1627631B1 (fr) 2012-02-08
AU769160C (en) 2006-02-23
CN1267089C (zh) 2006-08-02
CN1390121A (zh) 2003-01-08
PT1189602E (pt) 2007-05-31
PT1627631E (pt) 2012-05-21
AR068015A2 (es) 2009-10-28
NZ516077A (en) 2004-06-25
EP1818051A1 (fr) 2007-08-15
CA2376339A1 (fr) 2000-12-14
ES2280226T3 (es) 2007-09-16
EP1189602B1 (fr) 2007-02-21
MXPA01012751A (es) 2002-07-02
US7063864B1 (en) 2006-06-20
ZA200110087B (en) 2003-03-03
HK1045107B (zh) 2007-05-11
BR0011404B1 (pt) 2013-03-05
DE60033519T2 (de) 2007-10-31
CO5160317A1 (es) 2002-05-30
WO2000074659A1 (fr) 2000-12-14
EP1627631A3 (fr) 2006-03-15
TWI224510B (en) 2004-12-01
DK1627631T3 (da) 2012-04-30
US20070003620A1 (en) 2007-01-04
ATE544448T1 (de) 2012-02-15
JP2003520770A (ja) 2003-07-08
SI1189602T1 (sl) 2007-06-30
ATE354356T1 (de) 2007-03-15
FR2794646B1 (fr) 2001-09-21
FR2794646A1 (fr) 2000-12-15
DK1189602T3 (da) 2007-07-02
EP1627631A2 (fr) 2006-02-22
KR100676123B1 (ko) 2007-01-31
AU5539400A (en) 2000-12-28
DE60033519D1 (de) 2007-04-05
EP1189602A1 (fr) 2002-03-27
CY1107612T1 (el) 2013-03-13
AU769160B2 (en) 2004-01-15
CA2376339C (fr) 2011-05-17
KR20020031338A (ko) 2002-05-01
ES2379688T3 (es) 2012-04-30
HK1045107A1 (en) 2002-11-15
BRPI0011404B8 (pt) 2021-05-25
JP4296562B2 (ja) 2009-07-15

Similar Documents

Publication Publication Date Title
AR024313A1 (es) Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
AR039379A1 (es) Matriz para la liberacion sostenida, invariable e independiente de compuestos activos
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
UY26318A1 (es) Formas de administracion oral con liberacion total controlada de sustancia activa, encontrandose una misma sustancia activa en forma de al menos dos sales distintas que en la forma de administracion se encuentran en estado solido y que presentan dife
ID26378A (id) Metoda untuk memproduksi asam karboksilat dan alkohol
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
RS52891B (en) GASTRORE-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINE
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
ATE531368T1 (de) Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
IS5248A (is) Lyfjasamsetningar sem innihalda vorikónasól
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
ES2194480T3 (es) Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
PE20050066A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
HUP0201765A2 (hu) Maszkírozott ízű folyékony gyógyszerkészítmények
DE69824299D1 (de) Kupfer-enthaltende phosphorsäureester-derivate und verfahren zu ihrer herstellung, nahinfrarot-aborber, und im nahinfrarot absorbierende acrylharzzubereitungen
IT1257793B (it) Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato
FR2792527B1 (fr) Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
DE50013950D1 (de) Arzneistoffträger zur kontrollierten wirkstoffapplikation hergestellt aus lipidmatrix-arzneistoff-konjugaten (lak-partikel)
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
PE97199A1 (es) Composiciones solubilizadas de sertralina
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
DE50204203D1 (de) Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes

Legal Events

Date Code Title Description
FC Refusal